1 All‐cause mortality |
15 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
1.1 Up to 3 months' follow‐up after randomisation |
15 |
1861 |
Risk Ratio (M‐H, Random, 95% CI) |
0.90 [0.70, 1.15] |
1.2 At the end of treatment |
14 |
1824 |
Risk Ratio (M‐H, Random, 95% CI) |
0.87 [0.66, 1.15] |
1.3 At 1 year after randomisation |
3 |
1343 |
Risk Ratio (M‐H, Random, 95% CI) |
1.03 [0.91, 1.17] |
2 Health‐related quality of life |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Totals not selected |
2.1 Up to 3 months |
1 |
|
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
2.2 Up to 1 year |
1 |
|
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
3 Serious adverse events during treatment |
15 |
1861 |
Risk Ratio (M‐H, Random, 95% CI) |
1.05 [0.85, 1.29] |
4 Liver‐related mortality: up to 3 months' follow‐up after randomisation |
15 |
1861 |
Risk Ratio (M‐H, Random, 95% CI) |
0.89 [0.69, 1.14] |
5 Participants with any complication up to 3 months' follow‐up |
15 |
1861 |
Risk Ratio (M‐H, Random, 95% CI) |
1.04 [0.86, 1.27] |
6 Participants with non‐serious adverse events up to 3 months' follow‐up after randomisation |
4 |
160 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.99 [0.72, 5.48] |